PANEL DISCUSSION

Pharmaceutical Industry Perspectives on Expanding African American Enrollment in Clinical Trials

Michelle Papka, PhD Michael Irizarry, MD MPH Tony Pearson, JD MPH



PANEL DISCUSSION

Pharmaceutical Industry Perspectives on Expanding African American Enrollment in Clinical Trials

Michelle Papka, PhD Michael Irizarry, MD MPH Tony Pearson, JD MPH






- Introduction: Michelle Papka, PhD
- Pharma perspective:
 - Eisai: Michael Irizarry, MD MPH
 - Lilly: Tony Pearson, JD MPH

Why is important? What are they doing about it? Impact of those Efforts

• Discussion: What else should we be doing?





alzheimers

association

Focus on Black Americans:

- Twice as likely than older Whites to have Alzheimer's Disease
- 21.3% over the age of 70 are living with Alzheimer's
- Only 20% believe they have no barriers to excellent health care and support for AD/dementia
- 65% know somebody with Alzheimer's
- 55% think the significant cognitive decline is part of normal aging
- Disproportionate paid and unpaid caregiving costs



 8 2022 Alsheimerh Association* | All Rights Reserved Alsheimerh Association is a not-for- profit 500(c)(3) organization

Reasons Cited By U.S. Adults for Not being Interested in Clinical Trial Participation

 \frown


	White Americans	Hispanic Americans	Black Americans	Asian Americans	Native Americans
Don't want to be a guinea pig	49%	51%	69%	54%	51%
Treatment might cause sickness	37%	36%	45%	32%	18%
Time and cost might be too much	33%	26%	24%	43%	31%
Don't trust pharmaceutical companies	28%	22%	29%	19%	26%
Doubt there would be any benefit	26%	26%	21%	28%	36%
Might get placebo	17%	12%	14%	20%	9%
Don't trust medical research	10%	10%	24%	6%	16%
Unable to travel or get transportation	11%	11%	16%	19%	23%
Might not be treated fairly	3%	8%	22%	12%	10%



The Cognitive and Research Center of New Jersey, LLC

Mistrust Among Black Americans

• Past injustices





Individuals must be invited

Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?

David Wendler^{1*}, Raynard Kington², Jennifer Madans³, Gretchen Van Wye⁴, Heidi Christ-Schmidt⁵, Laura A. Pratt³, Otis W. Brawley⁶, Cary P. Gross⁷, Ezekiel Emanuel¹




Figure 2. Comparison of African-American versus non-Hispanic White Consent Rates




From: http://www.aral.com.au/ari/p-ywadsworth98.html

Blue indicates interview and non-intervention studies; red indicates clinical intervention studies. The graph indicates that most studies found that African-Americans were equally willing to participate in research as non-Hispanic white DOI: 10.1371/journal.pmed.0030019.g002



Why do we need to enroll more African Americans in AD clinical trials?

Black Americans underrepresented in Alzheimer's clinical trials: 2% - <5%



Underrepresentation of African Americans in clinical trials results in ongoing healthcare disparities.



Expanding African American Enrollment in Clinical Trials

22 June 2023

Michael C. Irizarry, MD, MPH SVP, Alzheimer Disease and Brain Health Eisai, Inc



. .

FOUR DECADES OF ALZHEIMER'S RESEARCH-NEVER GIVING UP

Eisai's human health care hhc mission:

We give first thought to patients and their families and increasing the benefits health care provides.






The primary focus of health care must always be the patient, the patient's family, and from a general vantage point, the public as a whole. These are the people we must serve.

- Haruo Naito, CEO of Eisai Co., Ltd.





- AD pathologic changes in the brain start 15-20 years before the development of symptoms⁴
- AD is a continuum consisting of a preclinical stage and progressing to AD dementia³


Areas of active investigation⁴: How are disease-modifying therapies interfering with the underlying pathophysiologic mechanism of disease?

AD, Alzheimer's disease.

1. Mathur R, et al. PLoS One. 2015; 10;e0118463. 2. Day RJ, et al. PLoS One. 2015;10e0132637. 3. Jack CR, et al. Alzheimers Dement. 2018;14:535-562. 4. Bateman RJ, et al. N Engl J Med. 2012;367:795-804.

11






FOUR DECADES OF ALZHEIMER'S RESEARCH – NEVER GIVING UP



CONFIDENTIAL AND PROPRIETARY. NOT TO BE USED IN PROMOTION. DO NOT COPY OR DISSEMINATE.

Clinical Trial Phases



https://hubpages.com/education/How-are-drugs-developed-and-approved-The-drug-development-process

🛉 healthy 🛉 affected

FOUR DECADES OF ALZHEIMER'S RESEARCH – NEVER GIVING UP



CONFIDENTIAL AND PROPRIETARY. NOT TO BE USED IN PROMOTION. DO NOT COPY OR DISSEMINATE.

Eisai Initiatives to Facilitate Access to Clinical Trials

- Investigators and sites with access to diverse communities
- Engagement with community centers and faith-based groups
- Decentralized clinical trial activities
 - Home infusions
 - Remote cognitive assessments
 - Remote safety assessments
- Community-based screening
- Partnership with advocacy organizations



Ongoing engagement with Black Health Matters on a12month program that includes social media posts, health content and videos encouraging enrollment and 2 featured AHEAD Study videos/commercials^{PM AHEAD}

Help us get AHEAD of Black Health Matters @BHMinfo · Jan 30 Alzheimer's disease! Black people only make up less than 5% of #Alzheimer's trial participants, despite having a higher risk of developing the disease. Join the AHEAD Study and help contribute to one day perhaps finding a treatment to event it. Visit Al y.org to learn more AHEADStudy.org AHEAD 1-800-AHEAD-70 There are benefits to participating in Alzheimer's research. Learn More Black Health Matters @BHMinfo - Oct 31 imers still isn't preventable. Join the AHEAD Study to work with orld-class memory researchers and investigational treatments. Find a al near you at A **Alzheimer's** on your mind? Join a study that aims to help prevent it. Find out more AHEAD AHEADStudy.org 1-800-AHFAD-70



Support for Diversity & Inclusion Activities in Alzheimer's Disease



UsAgainstAlzheimer's Brain Guide & Faith in Action Toolkit

- Brain Guide offers a private memory questionnaire and provides participants with resources just for them based on the answers provided.
- Faith in Action Toolkit provides brain health information and state-specific resources leaders of more than 30 churches can share with parishioners.



Bright Focus's Brain Info Live

Programs offer brain health education in live, local, patient-facing events and virtual activities in rural south Georgia and Passaic County, New Jersey



Alzheimer's Los Angeles is highly aware of the rich and vibrantly diverse nature of the large geographic area we serve, with dozens of distinct cultures and over 250 languages. We are committed to creating an environment that is open to discourse, listening, and learning from each other.



Alzheimer's LA Healthy Brain Initiative

• Educates the local African American and Hispanic communities about healthy lifestyle choices, understanding the difference between normal aging and the need for early diagnosis

A Dementia Alliance of North Carolina Rural Outreach Initiative

Increases education and access to dementia resources and support in rural counties in North Carolina



Analysis of Eligibility Criteria for AD Clinical Trials

- 10,804 US participants screened across 4 AD Phase 2 and Phase 3 trials
 - 193 (2%) Hispanic and Black
 - 2,224 (25%) Hispanic and White
 - 696 (7%) Non-Hispanic and Black
 - 7,017 (65%) Non-Hispanic and White
- 2,444 Randomized
 - 34 (1%) Hispanic and Black
 - 412 (17%) Hispanic and White
 - 63 (3%) Non-Hispanic and Black
 - 1918 (78%) Non-Hispanic and White
- Higher rate of screen failures in Hispanic and Black groups was due to amyloid criteria (i.e. did not have Alzheimer's disease as the cause of cognitive impairment)
 - Hispanic and Black: 56% screen failure by amyloid criteria
 - Hispanic and White: 64%
 - Non-Hispanic and Black: 67%
 - Nin-Hispanic and White: 32%

Grill J, AAIC 2022 and submitted

16



Conclusions

- Drug development in Alzheimer's disease has progressed rapidly with recent advances
 - Disease understanding
 - Experimental models of the disease
 - Biomarkers

17

- Increasing diversity in clinical trials is a priority
 - To be able to generalize the results of clinical trials to the real world population
 - Promote fair access to investigational therapies
 - Build trust in medical research, institutions, and therapies



FOUR DECADES OF ALZHEIMER'S RESEARCH – NEVER GIVING UP



CONFIDENTIAL AND PROPRIETARY. NOT TO BE USED IN PROMOTION. DO NOT COPY OR DISSEMINATE.



Eli Lilly: Tony Pearson, JD MPH

